Current Research and Scholarly Interests
Historically, children have represented an understudied “orphan” population in therapeutics, and traditional “one-size-fits-all” approaches to dosing remain inadequate given the heterogeneity introduced by growth and maturation. My research applies quantitative pharmacokinetic and pharmacodynamic (PK/PD) frameworks to develop individualized, evidence-based dosing strategies for neonates and children and to translate that evidence directly into clinical care through electronic health record–integrated precision dosing tools used in real time at the point of care. I apply this framework both to optimizing the use of established medications and to supporting clinical trials and early-phase drug development of novel and repurposed therapeutics, serving as a clinical pharmacologist providing PK/PD expertise from study design through analysis and interpretation.
In parallel, I lead a program of clinical and quality improvement research spanning the newborn continuum, from the delivery room through discharge. This work is built on the same underlying approach: identifying where current care does not align with the evidence, developing interventions and protocols that clinicians can reliably implement, and rigorously evaluating their impact on patient care.
Across both programs, and through mentoring residents, fellows, and junior faculty in clinical and translational research methodology, my goal is to take rigorous science and translate it into practical, evidence-based care at the bedside with the ultimate aim of improving the health and outcomes of children.
